Bhattacharyya, M <br/><br/>
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.  [electronic resource] 

 -  Cancer gene therapy  Oct 2011 
 - 734-43 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5500 
<br/><br/><label>Standard No.: </label>10.1038/cgt.2011.45  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adenoviruses, Human--genetics<br/>Animals<br/>Antineoplastic Agents--therapeutic use<br/>Cell Line, Tumor<br/>Cell Survival<br/>Combined Modality Therapy<br/>Cytopathogenic Effect, Viral<br/>Deoxycytidine--analogs & derivatives<br/>Fluorouracil--therapeutic use<br/>Gene Deletion<br/>Gene Expression Regulation, Viral--drug effects<br/>Humans<br/>Kaplan-Meier Estimate<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Nude<br/>Oncolytic Virotherapy<br/>Oncolytic Viruses--genetics<br/>Pancreatic Neoplasms--drug therapy<br/>Receptors, Virus--metabolism<br/>Retinoblastoma Protein--metabolism<br/>Virus Replication--genetics<br/>Xenograft Model Antitumor Assays<br/>Gemcitabine